Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) had its price objective lifted by stock analysts at Cantor Fitzgerald from $170.00 to $200.00 in a research note issued on Tuesday,Benzinga reports.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback